Neumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Bought by State Street Corp

State Street Corp increased its position in shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) by 65.3% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,790,707 shares of the company's stock after purchasing an additional 707,409 shares during the quarter. State Street Corp owned approximately 1.11% of Neumora Therapeutics worth $23,655,000 as of its most recent filing with the SEC.

Other hedge funds have also recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. boosted its holdings in shares of Neumora Therapeutics by 139.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 698,255 shares of the company's stock worth $9,224,000 after purchasing an additional 406,891 shares during the last quarter. Callan Capital LLC boosted its stake in Neumora Therapeutics by 222.6% during the second quarter. Callan Capital LLC now owns 661,194 shares of the company's stock worth $6,500,000 after buying an additional 456,207 shares during the last quarter. Auour Investments LLC purchased a new stake in Neumora Therapeutics in the 3rd quarter valued at $3,302,000. Cerity Partners LLC acquired a new stake in shares of Neumora Therapeutics in the 3rd quarter worth $3,209,000. Finally, Bank of New York Mellon Corp raised its holdings in shares of Neumora Therapeutics by 474.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 235,593 shares of the company's stock worth $2,316,000 after acquiring an additional 194,559 shares during the period. 47.65% of the stock is owned by institutional investors and hedge funds.

Neumora Therapeutics Stock Performance

Shares of NASDAQ NMRA traded up $0.27 during trading on Monday, reaching $11.12. The stock had a trading volume of 959,783 shares, compared to its average volume of 750,894. The business's 50-day moving average price is $11.61 and its 200-day moving average price is $11.55. Neumora Therapeutics, Inc. has a fifty-two week low of $8.33 and a fifty-two week high of $21.00. The company has a market cap of $1.80 billion, a P/E ratio of -5.95 and a beta of 3.34.

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.06). During the same period last year, the business earned ($1.14) EPS. Analysts forecast that Neumora Therapeutics, Inc. will post -1.61 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the stock. JPMorgan Chase & Co. lowered shares of Neumora Therapeutics from an "overweight" rating to a "neutral" rating and dropped their price objective for the company from $18.00 to $15.00 in a report on Tuesday, November 5th. Needham & Company LLC restated a "buy" rating and set a $23.00 price target on shares of Neumora Therapeutics in a report on Wednesday, November 13th. Royal Bank of Canada reiterated an "outperform" rating and issued a $29.00 price objective on shares of Neumora Therapeutics in a report on Friday, November 22nd. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $30.00 price target on shares of Neumora Therapeutics in a research note on Monday, December 16th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $23.40.

Insider Buying and Selling at Neumora Therapeutics

In related news, Director Matthew K. Fust sold 14,049 shares of the firm's stock in a transaction that occurred on Friday, October 18th. The shares were sold at an average price of $17.03, for a total value of $239,254.47. Following the sale, the director now owns 20,100 shares of the company's stock, valued at $342,303. This trade represents a 41.14 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Robert A. Lenz sold 5,563 shares of the stock in a transaction that occurred on Wednesday, October 9th. The shares were sold at an average price of $15.01, for a total transaction of $83,500.63. Following the completion of the sale, the insider now directly owns 322,966 shares in the company, valued at approximately $4,847,719.66. This represents a 1.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 26.40% of the stock is currently owned by corporate insiders.

Neumora Therapeutics Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.